Drug intelligence / Profile preview

berberine hydrochloride + mesalazine

Development stage
Preclinical
Lead developer
Tillotts Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

This is a fixed-dose combination of berberine hydrochloride and mesalazine. Berberine hydrochloride is an isoquinoline alkaloid with broad-spectrum antimicrobial, anti-inflammatory, and antidiarrheal properties, commonly used for gastrointestinal infections such as gastroenteritis and diarrhea. Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an aminosalicylate anti-inflammatory drug primarily used to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease. The combination has been studied for the treatment of distal ulcerative colitis, where it has shown enhanced efficacy in reducing inflammation markers compared to monotherapy with either agent[1][2][4][7]. Berberine acts by inhibiting bacterial DNA synthesis and modulating inflammatory pathways, while mesalazine inhibits cyclooxygenase and lipoxygenase pathways in the colon mucosa to reduce prostaglandin production.

Other names
盐酸小檗碱 + 美沙拉嗪
02

Targets

15-LOX (Lysyl Oxidase)DNA gyrasePLA2G4A (Cytosolic phospholipase A2 alpha)COX

Beyond the preview

Go deeper on berberine hydrochloride + mesalazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on berberine hydrochloride + mesalazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call